FDA Approves Bayer's Lynkuet, a Dual NK1/NK3 Hot-Flash Pill
Mahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Bayer
CONFIRMED87% CONFIDENCEBayer's[1] release is stamped "24 October 2025 | 19:25 PM Europe/Amsterdam" and opens "Berlin, October 24, 2025 - Bayer announced today that the U.S. Food and Drug Administration (FDA[2]) has approved elinzanetant".
The FDA approves Bayer's Lynkuet (elinzanetant), the first drug to block both the NK1 and NK3 receptors, as a hormone-free treatment for moderate to severe hot flashes of menopause.
1.00